EP0748338A4 - In vitro reifung von antikörpern mittels alanin 'scanning' mutagenese - Google Patents

In vitro reifung von antikörpern mittels alanin 'scanning' mutagenese

Info

Publication number
EP0748338A4
EP0748338A4 EP95911994A EP95911994A EP0748338A4 EP 0748338 A4 EP0748338 A4 EP 0748338A4 EP 95911994 A EP95911994 A EP 95911994A EP 95911994 A EP95911994 A EP 95911994A EP 0748338 A4 EP0748338 A4 EP 0748338A4
Authority
EP
European Patent Office
Prior art keywords
affinity
alanine scan
vitro antibody
antibody maturation
scan mutagenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95911994A
Other languages
English (en)
French (fr)
Other versions
EP0748338A1 (de
Inventor
Craig M Lewis
Steven W Ludmerer
Gregory F Hollis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0748338A1 publication Critical patent/EP0748338A1/de
Publication of EP0748338A4 publication Critical patent/EP0748338A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP95911994A 1994-03-04 1995-02-27 In vitro reifung von antikörpern mittels alanin 'scanning' mutagenese Withdrawn EP0748338A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20607994A 1994-03-04 1994-03-04
US206079 1994-03-04
PCT/US1995/002492 WO1995023813A1 (en) 1994-03-04 1995-02-27 In vitro antibody affinity maturation using alanine scanning mutagenesis

Publications (2)

Publication Number Publication Date
EP0748338A1 EP0748338A1 (de) 1996-12-18
EP0748338A4 true EP0748338A4 (de) 2001-03-28

Family

ID=22764890

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95911994A Withdrawn EP0748338A4 (de) 1994-03-04 1995-02-27 In vitro reifung von antikörpern mittels alanin 'scanning' mutagenese

Country Status (4)

Country Link
EP (1) EP0748338A4 (de)
JP (1) JPH09509835A (de)
CA (1) CA2183550A1 (de)
WO (1) WO1995023813A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
IL131406A0 (en) 1997-02-21 2001-01-28 Genentech Inc Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6025158A (en) * 1997-02-21 2000-02-15 Genentech, Inc. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
DE19728697C1 (de) * 1997-07-04 1999-03-25 Deutsches Krebsforsch Humaner Antikörper gegen ein Fusions(poly)peptid bzw. -protein, das einen Anteil von mindestens sechs Histidinen aufweist
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
ES2609102T3 (es) * 2003-06-27 2017-04-18 Bioren, LLC Mutagénesis por revisión
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
MX2008012896A (es) 2006-04-05 2008-10-14 Abbott Biotech Ltd Purificacion de anticuerpos.
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
US9127052B2 (en) 2010-06-29 2015-09-08 Centre National De La Recherche Scientifique LLT-1 antibodies with new functional properties
CN103339145A (zh) * 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CRAIG M. LEWIS ET AL: "Use of alanine scanning mutagenesis to improve the affinity of an anti-gp120 (HIV)antibody", JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT - KEYSTONE SYMPOSIUM ON ANTIBODY ENGINEERING, vol. 32, 7 March 1994 (1994-03-07) - 13 March 1994 (1994-03-13), XP000943396 *
LISA K. DENZIN ET AL.: "Mutational analysis of active site contact residues in anti-fluorescein monoclonal antibody", MOLECULAR IMMUNOLOGY, vol. 30, no. 15, 1993, pages 1331 - 1345, XP000943436 *
MIROSLAW K. GORNY ET AL.: "Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type I", JOURNAL OF VIROLOGY, vol. 68, no. 12, 15 December 1994 (1994-12-15), pages 8312-8320, XP000943394 *
ROBERT F. KELLEY AND MARK P. O'CONNELL: "Thermodynamic analysis of an antibody functional epitope", BIOCHEMISTRY, vol. 32, 1993, pages 6828 - 6835, XP000943393 *
See also references of WO9523813A1 *

Also Published As

Publication number Publication date
JPH09509835A (ja) 1997-10-07
EP0748338A1 (de) 1996-12-18
CA2183550A1 (en) 1995-09-08
WO1995023813A1 (en) 1995-09-08

Similar Documents

Publication Publication Date Title
EP0748338A4 (de) In vitro reifung von antikörpern mittels alanin 'scanning' mutagenese
LU91029I2 (fr) Conjugués de l'interféron
PT8472T (pt) Cuecas de homem
FI963475A7 (fi) Fibroblastin kasvutekijä 10
KR890016457U (ko) 가스봄베의 봄베밸브
KR960003695U (ko) 남성용 팬티
ITTO931015A1 (it) Basamento per cilindri e procedimento per la sua realizzazione.
EP0751770A4 (de) 8-substituierte tetrahydro-beta-carboline
FR2776456B1 (fr) Perfectionnement a l'acquisition d'image par balayage pousse-balai
EP0888126A4 (de) Anti-idiotypische antikörperimpfstoffe
IT244320Y1 (it) "mobile spostabile per lavori da parrucchiere in ospedali e simili"
IT1286061B1 (it) Procedimento per produrre un anello per un commutatore nonche' commutatore prodotto in base ad esso
IT1292506B1 (it) Trave a doppia pendenza in due meta'
FR2744917B1 (fr) Composition therapeutique a base d'acetaminophene
KR960003693U (ko) 남성용 팬티
KR970053199U (ko) 남성용팬티
KR970020904U (ko) 어린이용 방독면
KR970015890U (ko) 남성팬티
KR970050665U (ko) 남성용 팬티
FR2773126B3 (fr) Plaque d'immatriculation amovible
FR2753260B1 (fr) Perfectionnements concernant un moyen d'eclairage
KR930017816U (ko) 유희용 다리
ITTO940810A0 (it) "sedia"
KR960000305U (ko) 2개의 앉음판 구조로 된 의자
BR9401273A (pt) Bermuda sexual masculina

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010212

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020901